ทำไมราคาหุ้น INTELLIA THERAPEUTICS ถึงเพิ่มขึ้น?
ฝ่ายกระทิงกล่าวว่า
Clinical efficacy
Phase 3 HAELO results demonstrated large and statistically significant reductions in hereditary angioedema attack rates, with a substantial share of treated patients becoming attack‑ and treatment‑free, which could bolster clinician and investor confidence.
Regulatory advancement
A rolling biologics license application has been initiated for lonvo‑z, advancing regulatory progress and positioning the therapy for potential approval as a first in vivo gene‑editing treatment.
Durable one‑time therapy potential
A one‑time gene‑editing infusion offers the potential to replace lifelong chronic therapy for hereditary angioedema, presenting a differentiated commercial value proposition if durability and safety are confirmed.
Commercial adoption risk
Commercial adoption may be constrained because uptake depends on demonstrated durability, long‑term safety, infusion logistics, and payor willingness to reimburse a front‑loaded one‑time therapy.
Safety concerns
Observed liver enzyme elevations and higher rates of infusion‑related reactions in treated patients create ongoing safety monitoring needs that could slow regulatory review and clinician acceptance.
Regulatory and trial delays
Regulators could require enhanced early monitoring or expanded safety datasets before resuming or advancing trials, and prior holds on cardiac programs highlight the risk of delays and added regulatory burden.
